Pharma major Sun Pharma on Friday reported a 27% year-on-year (YoY) increase in net profit to Rs 2,895 crore for the June-ended quarter, compared with Rs 2,279 crore in the same period last year. Revenue from operations rose 10.5% YoY to Rs 15,300 crore during the reporting period.The profit growth was driven by strong performance in India and its global innovative medicines business, even as US formulations sales declined. EBITDA stood at Rs 4,418 crore, up 3% from a year earlier, while the EBITDA margin came in at 28.9%.Sun Pharma MD Kirti Ganorkar said the quarter was driven by strong momentum in India and the innovative medicines business, which posted robust growth across the US and international markets. "Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the US and international regions," Ganorkar said.He added that recent semaglutide approvals in India, Brazil and South Africa demonstrated the company’s capabilities in complex peptide products. Ganorkar also said Organon shareholders had approved Sun Pharma’s proposed acquisition, which remains on track to close in early 2027.